Other
Reduction to finance leases
Vertex Pharmaceuticals Reduction to finance leases remained flat by 0.0% to $68.83M in Q4 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionOther
CategoryLeverage
SignalHigher is better
VolatilityStable
First reportedQ1 2025
Last reportedQ4 2025Feb 13, 2026
How to read this metric
Consistent reductions indicate active management and repayment of long-term lease liabilities.
Detailed definition
Represents the principal portion of payments made toward finance lease obligations. This reduces the total liability rec...
Peer comparison
Standard metric for companies with significant capital lease obligations.
Metric ID:
other_reduction_to_finance_leasesHistorical Data
1 years
| FY'25 | |
|---|---|
| Value | $275.30M |
Reduction to finance leases at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's reduction to finance leases?
- Vertex Pharmaceuticals (VRTX) reported reduction to finance leases of $68.83M in Q4 2025.
- What does reduction to finance leases mean?
- The principal repayment portion of finance lease obligations.